Progyny, Inc. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Progyny, Inc. (PGNY) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$566.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-08-07
- Progyny, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-06-30 was $584.00K, a 45.88% decline year-over-year.
- Progyny, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-03-31 was -$1.15M.
- Progyny, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $434.00K.
- Progyny, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was $459.00K.
- Progyny, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $866.00K, a 59.05% decline from fiscal 2024.
- Progyny, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $2.12M, a 51.13% decline from fiscal 2023.
- Progyny, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $4.33M.
- Progyny, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was $0.00.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $584.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$566.00K 10-Q · filed 2026-08-07 | -$132.00K derived: sum of 3 quarters · filed 2026-08-07 | $327.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$1.15M 10-Q · filed 2026-05-08 | -$716.00K derived: sum of 2 quarters · filed 2026-05-08 | -$257.00K derived: sum of 3 quarters · filed 2026-05-08 | $822.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $893.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.97M derived: sum of 3 quarters · filed 2026-08-07 | $866.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $459.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.54M derived: sum of 2 quarters · filed 2026-08-07 | $432.00K 10-Q · filed 2025-11-07 | -$1.21M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$27.00K 10-Q · filed 2026-08-07 | -$1.67M derived: sum of 3 quarters · filed 2026-08-07 | -$4.90M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$1.11M 10-Q · filed 2026-05-08 | -$2.75M derived: sum of 2 quarters · filed 2026-05-08 | -$5.98M derived: sum of 3 quarters · filed 2026-05-08 | -$2.39M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$4.87M derived: sum of 2 quarters · filed 2026-02-27 | -$1.28M derived: sum of 3 quarters · filed 2026-02-27 | $2.12M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$3.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $364.00K derived: sum of 2 quarters · filed 2025-11-07 | $3.76M 10-Q · filed 2025-11-07 | $5.39M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $6.99M 10-Q · filed 2025-08-08 | $8.61M derived: sum of 3 quarters · filed 2026-02-27 | $9.99M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $3.40M 10-Q · filed 2025-05-09 | $5.02M derived: sum of 2 quarters · filed 2026-02-27 | $6.40M derived: sum of 3 quarters · filed 2026-02-27 | $7.22M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.00M derived: sum of 2 quarters · filed 2026-02-27 | $3.83M derived: sum of 3 quarters · filed 2026-02-27 | $4.33M 10-K · filed 2026-02-27 |
| 2023-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.20M derived: sum of 2 quarters · filed 2024-08-07 | $2.70M 10-Q · filed 2023-11-08 | $2.70M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $822.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.32M 10-Q · filed 2024-08-07 | $1.32M derived: sum of 3 quarters · filed 2025-03-03 | $1.32M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $502.00K 10-Q · filed 2024-05-10 | $502.00K derived: sum of 2 quarters · filed 2025-03-03 | $502.00K derived: sum of 3 quarters · filed 2025-03-03 | $502.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $0.00 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |